Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Clinical evidence

PsiDeR

40 evidence topics · 3 sources

Objective
Location and study date
Registry dates and location
FieldRegistry entry
Study start (actual)“2021-06-21”
Primary completion (actual)“2024-12-18”
Study completion (actual)“2024-12-18”
Location“Clinical Research Facility, King's College Hospital”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using recruitment and retention rates as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Minimization factors and baseline demographics by arm
CharacteristicPlacebo (N = 30)Psilocybin (N = 30)Overall (N = 60)
Female, n (%)“15 (50%)”View highlighted excerpt for this quote“15 (50%)”View highlighted excerpt for this quote“30 (50%)”View highlighted excerpt for this quote
Age group 60 or older, n (%)“3 (10%)”View highlighted excerpt for this quote“3 (10%)”View highlighted excerpt for this quote“6 (10%)”View highlighted excerpt for this quote
Past psilocybin use, n (%)“5 (17%)”View highlighted excerpt for this quote“4 (13%)”View highlighted excerpt for this quote“9 (15%)”View highlighted excerpt for this quote
Age at randomization, median (IQR)“40.2 (33.7−52.0)”View highlighted excerpt for this quote“41.7 (38.6−57.0)”View highlighted excerpt for this quote“40.8 (35.2−52.3)”View highlighted excerpt for this quote
HAM-D-17 score, median (IQR)“17.0 (15.0−21.0)”View highlighted excerpt for this quote“18.5 (16.0−21.0)”View highlighted excerpt for this quote“18.0 (15.0−21.0)”View highlighted excerpt for this quote
Ethnicity White, n (%)“24 (80%)”View highlighted excerpt for this quote“21 (70%)”View highlighted excerpt for this quote“45 (75%)”View highlighted excerpt for this quote
Postgraduate degree, n (%)“14 (47%)”View highlighted excerpt for this quote“11 (37%)”View highlighted excerpt for this quote“25 (42%)”View highlighted excerpt for this quote
Full-time employed, n (%)“11 (37%)”View highlighted excerpt for this quote“15 (50%)”View highlighted excerpt for this quote“26 (43%)”View highlighted excerpt for this quote
First-degree family history of depression, n (%)“15 (50%)”View highlighted excerpt for this quote“18 (60%)”View highlighted excerpt for this quote“33 (55%)”View highlighted excerpt for this quote
Years spent with feelings of significant depression, mean (s.d.)“19.2 (10.3)”View highlighted excerpt for this quote“20.9 (10.2)”View highlighted excerpt for this quote“20.0 (10.2)”View highlighted excerpt for this quote
Maudsley Staging Method score at screening, median (IQR)“8.0 (7.0−9.0)”View highlighted excerpt for this quote“8.0 (7.0−10.0)”View highlighted excerpt for this quote“8.0 (7.0−9.5)”View highlighted excerpt for this quote
Efficacy results
Primary feasibility outcomes
Health-related quality of life and patient-reported outcomes
Adjusted mean differences in patient-reported outcomes
Scale and timepointMean difference (95% CI)Cohen's d (95% CI)
QIDS-SR-16, Week 3“−5.48 (−7.85 to −3.12)”View highlighted excerpt for this quote“−1.19 (−1.7 to −0.67)”View highlighted excerpt for this quote
QIDS-SR-16, Week 6“−5.63 (−8.00 to −3.27)”View highlighted excerpt for this quote“−1.22 (−1.73 to −0.71)”View highlighted excerpt for this quote
GAD-7, Week 3“−4.85 (−6.96 to −2.74)”View highlighted excerpt for this quote“−1.00 (−1.44 to −0.57)”View highlighted excerpt for this quote
GAD-7, Week 6“−4.54 (−6.64 to −2.44)”View highlighted excerpt for this quote“−0.94 (−1.37 to −0.50)”View highlighted excerpt for this quote
EQ-5D-5L VAS, Week 3“12.46 (3.39−21.54)”View highlighted excerpt for this quote“0.62 (0.17−1.07)”View highlighted excerpt for this quote
EQ-5D-5L VAS, Week 6“10.69 (1.63−19.75)”View highlighted excerpt for this quote“0.53 (0.08−0.98)”View highlighted excerpt for this quote
WSAS, Week 3“−8.20 (−12.09 to −4.30)”View highlighted excerpt for this quote“−1.26 (−1.86 to −0.66)”View highlighted excerpt for this quote
WSAS, Week 6“−9.22 (−13.08 to −5.36)”View highlighted excerpt for this quote“−1.42 (−2.02 to −0.83)”View highlighted excerpt for this quote
M3VAS, Week 3“45.33 (19.69−70.96)”View highlighted excerpt for this quote“1.17 (0.51−1.83)”View highlighted excerpt for this quote
M3VAS, Week 6“36.42 (10.80−62.04)”View highlighted excerpt for this quote“0.94 (0.28−1.60)”View highlighted excerpt for this quote
WEMWBS, Week 3“10.48 (6.57−14.40)”View highlighted excerpt for this quote“1.76 (1.10−2.42)”View highlighted excerpt for this quote
WEMWBS, Week 6“9.44 (5.55−13.32)”View highlighted excerpt for this quote“1.59 (0.93−2.24)”View highlighted excerpt for this quote
Safety results
Nonserious adverse events during the randomized phase (randomization to Week 6)
CategoryPlacebo (123 events; 28 reporters)Psilocybin (164 events; 30 reporters)Overall (287 events; 58 reporters)
Neurological, events (reporters)“32 (17)”View highlighted excerpt for this quote“53 (26)”View highlighted excerpt for this quote“85 (43)”View highlighted excerpt for this quote
Mood/psychological, events (reporters)“13 (9)”View highlighted excerpt for this quote“30 (18)”View highlighted excerpt for this quote“43 (27)”View highlighted excerpt for this quote
Respiratory infection, events (reporters)“24 (16)”View highlighted excerpt for this quote“12 (11)”View highlighted excerpt for this quote“36 (27)”View highlighted excerpt for this quote
Gastrointestinal, events (reporters)“8 (6)”View highlighted excerpt for this quote“15 (12)”View highlighted excerpt for this quote“23 (18)”View highlighted excerpt for this quote
Musculoskeletal/pain, events (reporters)“13 (11)”View highlighted excerpt for this quote“14 (9)”View highlighted excerpt for this quote“27 (20)”View highlighted excerpt for this quote
Medication or substance related, events (reporters)“5 (5)”View highlighted excerpt for this quote“10 (9)”View highlighted excerpt for this quote“15 (14)”View highlighted excerpt for this quote
General fatigue/tiredness, events (reporters)“4 (4)”View highlighted excerpt for this quote“8 (8)”View highlighted excerpt for this quote“12 (12)”View highlighted excerpt for this quote
Related to study medication, n (%)“2 (2%)”View highlighted excerpt for this quote“29 (18%)”View highlighted excerpt for this quote“31 (11%)”View highlighted excerpt for this quote
Possibly related, n (%)“16 (13%)”View highlighted excerpt for this quote“56 (34%)”View highlighted excerpt for this quote“72 (25%)”View highlighted excerpt for this quote
Mild intensity, n (%)“77 (63%)”View highlighted excerpt for this quote“111 (68%)”View highlighted excerpt for this quote“188 (66%)”View highlighted excerpt for this quote
Moderate intensity, n (%)“45 (37%)”View highlighted excerpt for this quote“48 (29%)”View highlighted excerpt for this quote“93 (32%)”View highlighted excerpt for this quote
Severe intensity, n (%)“1 (1%)”View highlighted excerpt for this quote“5 (3%)”View highlighted excerpt for this quote“6 (2%)”View highlighted excerpt for this quote
Adverse events of special interest, n (%)“0 (0%)”View highlighted excerpt for this quote“0 (0%)”View highlighted excerpt for this quote“0 (0%)”View highlighted excerpt for this quote
Study limitations
Summary: functional unblinding, inactive placebo with little placebo response, feasibility design, single site, sample composition

PsiDeR was a single-site feasibility trial of 60 participants with 6 weeks of follow-up and no hypothesis testing. Blinding was assessed in a subsample of 23 participants after a measure was introduced part-way through the trial: 13 of 13 (100%) in the psilocybin arm and 7 of 10 (70%) in the placebo arm correctly guessed their allocation, and the authors state that “expectancy effects in both groups likely account for some of the between-group difference observed”. The placebo arm did not show meaningful reductions in MADRS or QIDS-SR scores, and the authors note that active placebos or subperceptual doses may be more appropriate for efficacy trials. The sample was highly educated, recruitment targets were not met for Black, African, Caribbean or Black British participants, and about half of participants used facilities opened under a later financial agreement with COMPASS Pathways.